Loading…

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma

Multiple myeloma (MM), a clonal plasma cell disorder, disrupts the bones’ hematopoiesis and microenvironment homeostasis and ability to mediate an immune response against malignant clones. Despite prominent survival improvement with newer treatment modalities since the 2000s, MM is still considered...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2021-05, Vol.22 (11), p.5707
Main Authors: Von Suskil, Max, Sultana, Kazi Nasrin, Elbezanti, Weam Othman, Al-Odat, Omar S., Chitren, Robert, Tiwari, Amit K., Challagundla, Kishore B., Srivastava, Sandeep Kumar, Jonnalagadda, Subash C., Budak-Alpdogan, Tulin, Pandey, Manoj K.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c427t-5db3669ea192fdceb4d9087cbf01387f9da5df158eeb403b2a059a31ece287493
cites cdi_FETCH-LOGICAL-c427t-5db3669ea192fdceb4d9087cbf01387f9da5df158eeb403b2a059a31ece287493
container_end_page
container_issue 11
container_start_page 5707
container_title International journal of molecular sciences
container_volume 22
creator Von Suskil, Max
Sultana, Kazi Nasrin
Elbezanti, Weam Othman
Al-Odat, Omar S.
Chitren, Robert
Tiwari, Amit K.
Challagundla, Kishore B.
Srivastava, Sandeep Kumar
Jonnalagadda, Subash C.
Budak-Alpdogan, Tulin
Pandey, Manoj K.
description Multiple myeloma (MM), a clonal plasma cell disorder, disrupts the bones’ hematopoiesis and microenvironment homeostasis and ability to mediate an immune response against malignant clones. Despite prominent survival improvement with newer treatment modalities since the 2000s, MM is still considered a non-curable disease. Patients experience disease recurrence episodes with clonal evolution, and with each relapse disease comes back with a more aggressive phenotype. Bruton’s Tyrosine Kinase (BTK) has been a major target for B cell clonal disorders and its role in clonal plasma cell disorders is under active investigation. BTK is a cytosolic kinase which plays a major role in the immune system and its related malignancies. The BTK pathway has been shown to provide survival for malignant clone and multiple myeloma stem cells (MMSCs). BTK also regulates the malignant clones’ interaction with the bone marrow microenvironment. Hence, BTK inhibition is a promising therapeutic strategy for MM patients. In this review, the role of BTK and its signal transduction pathways are outlined in the context of MM.
doi_str_mv 10.3390/ijms22115707
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b26cc9bd38c74bec9e24eaac4808073d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b26cc9bd38c74bec9e24eaac4808073d</doaj_id><sourcerecordid>2536466748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-5db3669ea192fdceb4d9087cbf01387f9da5df158eeb403b2a059a31ece287493</originalsourceid><addsrcrecordid>eNpVkbtOxDAQRS0E4t3xASkpCPiV2G6QAPESIJqlthx7sniVxIudIG3Hb_B7fAmBXaGlmtHcqzOjuQgdEXzKmMJnftYmSgkpBBYbaJdwSnOMS7G51u-gvZRmGFNGC7WNdhjHgigidpG8jEMfuq-Pz5RNFjEk30H24DuTIJuYOIXed9PMd9nT0PR-3kD2tIAmtOYAbdWmSXC4qvvo5eZ6cnWXPz7f3l9dPOaWU9HnhatYWSowRNHaWai4U1gKW9WYMClq5UzhalJIGCXMKmpwoQwjYIFKwRXbR_dLrgtmpufRtyYudDBe_w5CnGoTe28b0BUtrVWVY9IKXoFVQDkYY7nEEgvmRtb5kjUfqhbGa7o-muYf9L_S-Vc9De9aEiWFECPgeAWI4W2A1OvWJwtNYzoIQ9K0YCUvS8HlaD1ZWu341BSh_ltDsP4JTq8Hx74BXY6MYQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2536466748</pqid></control><display><type>article</type><title>Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma</title><source>PubMed Central(OpenAccess)</source><source>ProQuest Publicly Available Content database</source><creator>Von Suskil, Max ; Sultana, Kazi Nasrin ; Elbezanti, Weam Othman ; Al-Odat, Omar S. ; Chitren, Robert ; Tiwari, Amit K. ; Challagundla, Kishore B. ; Srivastava, Sandeep Kumar ; Jonnalagadda, Subash C. ; Budak-Alpdogan, Tulin ; Pandey, Manoj K.</creator><creatorcontrib>Von Suskil, Max ; Sultana, Kazi Nasrin ; Elbezanti, Weam Othman ; Al-Odat, Omar S. ; Chitren, Robert ; Tiwari, Amit K. ; Challagundla, Kishore B. ; Srivastava, Sandeep Kumar ; Jonnalagadda, Subash C. ; Budak-Alpdogan, Tulin ; Pandey, Manoj K.</creatorcontrib><description>Multiple myeloma (MM), a clonal plasma cell disorder, disrupts the bones’ hematopoiesis and microenvironment homeostasis and ability to mediate an immune response against malignant clones. Despite prominent survival improvement with newer treatment modalities since the 2000s, MM is still considered a non-curable disease. Patients experience disease recurrence episodes with clonal evolution, and with each relapse disease comes back with a more aggressive phenotype. Bruton’s Tyrosine Kinase (BTK) has been a major target for B cell clonal disorders and its role in clonal plasma cell disorders is under active investigation. BTK is a cytosolic kinase which plays a major role in the immune system and its related malignancies. The BTK pathway has been shown to provide survival for malignant clone and multiple myeloma stem cells (MMSCs). BTK also regulates the malignant clones’ interaction with the bone marrow microenvironment. Hence, BTK inhibition is a promising therapeutic strategy for MM patients. In this review, the role of BTK and its signal transduction pathways are outlined in the context of MM.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms22115707</identifier><identifier>PMID: 34071917</identifier><language>eng</language><publisher>MDPI</publisher><subject>Bruton’s Tyrosine Kinase (BTK) inhibitors ; drug development ; microenvironment ; multiple myeloma ; resistance ; Review</subject><ispartof>International journal of molecular sciences, 2021-05, Vol.22 (11), p.5707</ispartof><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-5db3669ea192fdceb4d9087cbf01387f9da5df158eeb403b2a059a31ece287493</citedby><cites>FETCH-LOGICAL-c427t-5db3669ea192fdceb4d9087cbf01387f9da5df158eeb403b2a059a31ece287493</cites><orcidid>0000-0001-6498-9119 ; 0000-0001-5234-1235 ; 0000-0002-7427-7155 ; 0000-0002-2767-2929</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198777/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198777/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids></links><search><creatorcontrib>Von Suskil, Max</creatorcontrib><creatorcontrib>Sultana, Kazi Nasrin</creatorcontrib><creatorcontrib>Elbezanti, Weam Othman</creatorcontrib><creatorcontrib>Al-Odat, Omar S.</creatorcontrib><creatorcontrib>Chitren, Robert</creatorcontrib><creatorcontrib>Tiwari, Amit K.</creatorcontrib><creatorcontrib>Challagundla, Kishore B.</creatorcontrib><creatorcontrib>Srivastava, Sandeep Kumar</creatorcontrib><creatorcontrib>Jonnalagadda, Subash C.</creatorcontrib><creatorcontrib>Budak-Alpdogan, Tulin</creatorcontrib><creatorcontrib>Pandey, Manoj K.</creatorcontrib><title>Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma</title><title>International journal of molecular sciences</title><description>Multiple myeloma (MM), a clonal plasma cell disorder, disrupts the bones’ hematopoiesis and microenvironment homeostasis and ability to mediate an immune response against malignant clones. Despite prominent survival improvement with newer treatment modalities since the 2000s, MM is still considered a non-curable disease. Patients experience disease recurrence episodes with clonal evolution, and with each relapse disease comes back with a more aggressive phenotype. Bruton’s Tyrosine Kinase (BTK) has been a major target for B cell clonal disorders and its role in clonal plasma cell disorders is under active investigation. BTK is a cytosolic kinase which plays a major role in the immune system and its related malignancies. The BTK pathway has been shown to provide survival for malignant clone and multiple myeloma stem cells (MMSCs). BTK also regulates the malignant clones’ interaction with the bone marrow microenvironment. Hence, BTK inhibition is a promising therapeutic strategy for MM patients. In this review, the role of BTK and its signal transduction pathways are outlined in the context of MM.</description><subject>Bruton’s Tyrosine Kinase (BTK) inhibitors</subject><subject>drug development</subject><subject>microenvironment</subject><subject>multiple myeloma</subject><subject>resistance</subject><subject>Review</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkbtOxDAQRS0E4t3xASkpCPiV2G6QAPESIJqlthx7sniVxIudIG3Hb_B7fAmBXaGlmtHcqzOjuQgdEXzKmMJnftYmSgkpBBYbaJdwSnOMS7G51u-gvZRmGFNGC7WNdhjHgigidpG8jEMfuq-Pz5RNFjEk30H24DuTIJuYOIXed9PMd9nT0PR-3kD2tIAmtOYAbdWmSXC4qvvo5eZ6cnWXPz7f3l9dPOaWU9HnhatYWSowRNHaWai4U1gKW9WYMClq5UzhalJIGCXMKmpwoQwjYIFKwRXbR_dLrgtmpufRtyYudDBe_w5CnGoTe28b0BUtrVWVY9IKXoFVQDkYY7nEEgvmRtb5kjUfqhbGa7o-muYf9L_S-Vc9De9aEiWFECPgeAWI4W2A1OvWJwtNYzoIQ9K0YCUvS8HlaD1ZWu341BSh_ltDsP4JTq8Hx74BXY6MYQ</recordid><startdate>20210527</startdate><enddate>20210527</enddate><creator>Von Suskil, Max</creator><creator>Sultana, Kazi Nasrin</creator><creator>Elbezanti, Weam Othman</creator><creator>Al-Odat, Omar S.</creator><creator>Chitren, Robert</creator><creator>Tiwari, Amit K.</creator><creator>Challagundla, Kishore B.</creator><creator>Srivastava, Sandeep Kumar</creator><creator>Jonnalagadda, Subash C.</creator><creator>Budak-Alpdogan, Tulin</creator><creator>Pandey, Manoj K.</creator><general>MDPI</general><general>MDPI AG</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6498-9119</orcidid><orcidid>https://orcid.org/0000-0001-5234-1235</orcidid><orcidid>https://orcid.org/0000-0002-7427-7155</orcidid><orcidid>https://orcid.org/0000-0002-2767-2929</orcidid></search><sort><creationdate>20210527</creationdate><title>Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma</title><author>Von Suskil, Max ; Sultana, Kazi Nasrin ; Elbezanti, Weam Othman ; Al-Odat, Omar S. ; Chitren, Robert ; Tiwari, Amit K. ; Challagundla, Kishore B. ; Srivastava, Sandeep Kumar ; Jonnalagadda, Subash C. ; Budak-Alpdogan, Tulin ; Pandey, Manoj K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-5db3669ea192fdceb4d9087cbf01387f9da5df158eeb403b2a059a31ece287493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bruton’s Tyrosine Kinase (BTK) inhibitors</topic><topic>drug development</topic><topic>microenvironment</topic><topic>multiple myeloma</topic><topic>resistance</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Von Suskil, Max</creatorcontrib><creatorcontrib>Sultana, Kazi Nasrin</creatorcontrib><creatorcontrib>Elbezanti, Weam Othman</creatorcontrib><creatorcontrib>Al-Odat, Omar S.</creatorcontrib><creatorcontrib>Chitren, Robert</creatorcontrib><creatorcontrib>Tiwari, Amit K.</creatorcontrib><creatorcontrib>Challagundla, Kishore B.</creatorcontrib><creatorcontrib>Srivastava, Sandeep Kumar</creatorcontrib><creatorcontrib>Jonnalagadda, Subash C.</creatorcontrib><creatorcontrib>Budak-Alpdogan, Tulin</creatorcontrib><creatorcontrib>Pandey, Manoj K.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Von Suskil, Max</au><au>Sultana, Kazi Nasrin</au><au>Elbezanti, Weam Othman</au><au>Al-Odat, Omar S.</au><au>Chitren, Robert</au><au>Tiwari, Amit K.</au><au>Challagundla, Kishore B.</au><au>Srivastava, Sandeep Kumar</au><au>Jonnalagadda, Subash C.</au><au>Budak-Alpdogan, Tulin</au><au>Pandey, Manoj K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma</atitle><jtitle>International journal of molecular sciences</jtitle><date>2021-05-27</date><risdate>2021</risdate><volume>22</volume><issue>11</issue><spage>5707</spage><pages>5707-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Multiple myeloma (MM), a clonal plasma cell disorder, disrupts the bones’ hematopoiesis and microenvironment homeostasis and ability to mediate an immune response against malignant clones. Despite prominent survival improvement with newer treatment modalities since the 2000s, MM is still considered a non-curable disease. Patients experience disease recurrence episodes with clonal evolution, and with each relapse disease comes back with a more aggressive phenotype. Bruton’s Tyrosine Kinase (BTK) has been a major target for B cell clonal disorders and its role in clonal plasma cell disorders is under active investigation. BTK is a cytosolic kinase which plays a major role in the immune system and its related malignancies. The BTK pathway has been shown to provide survival for malignant clone and multiple myeloma stem cells (MMSCs). BTK also regulates the malignant clones’ interaction with the bone marrow microenvironment. Hence, BTK inhibition is a promising therapeutic strategy for MM patients. In this review, the role of BTK and its signal transduction pathways are outlined in the context of MM.</abstract><pub>MDPI</pub><pmid>34071917</pmid><doi>10.3390/ijms22115707</doi><orcidid>https://orcid.org/0000-0001-6498-9119</orcidid><orcidid>https://orcid.org/0000-0001-5234-1235</orcidid><orcidid>https://orcid.org/0000-0002-7427-7155</orcidid><orcidid>https://orcid.org/0000-0002-2767-2929</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2021-05, Vol.22 (11), p.5707
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_b26cc9bd38c74bec9e24eaac4808073d
source PubMed Central(OpenAccess); ProQuest Publicly Available Content database
subjects Bruton’s Tyrosine Kinase (BTK) inhibitors
drug development
microenvironment
multiple myeloma
resistance
Review
title Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A58%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bruton%E2%80%99s%20Tyrosine%20Kinase%20Targeting%20in%20Multiple%20Myeloma&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Von%20Suskil,%20Max&rft.date=2021-05-27&rft.volume=22&rft.issue=11&rft.spage=5707&rft.pages=5707-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms22115707&rft_dat=%3Cproquest_doaj_%3E2536466748%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c427t-5db3669ea192fdceb4d9087cbf01387f9da5df158eeb403b2a059a31ece287493%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2536466748&rft_id=info:pmid/34071917&rfr_iscdi=true